On a GLP-1? This Is the Workout Plan That Helps You Keep Muscle
Wednesday, April 1, 2026 – Thursday, April 2 - Physical activity is crucial when you’re taking this medication.
New GLP-1 Pill Wins Speedy Approval for Weight Loss
Wednesday, April 1, 2026 – Thursday, April 2 - (MedPage Today) -- The FDA has approved a second oral GLP-1 receptor agonist for weight loss in adults with obesity or overweight and weight-related comorbidities.
A once-daily tablet, orforglipron (Foundayo) is indicated in conjunction with a...
FDA Approves Eli Lilly’s GLP-1 Pill
Wednesday, April 1, 2026 – Thursday, April 2 - Eli Lilly’s once-daily Foundayo is the second obesity pill to receive FDA approval. It will compete with Novo Nordisk’s pill version of Wegovy.
T2D Patient-Reported Outcomes Improved After Switching From Dulaglutide to Tirzepatide
Wednesday, April 1, 2026 – WEDNESDAY, April 1, 2026 -- For adults with type 2 diabetes (T2D) who were not achieving glycemic control while receiving a stable dose of dulaglutide, switching to tirzepatide is associated with improvement in patient-reported outcomes (PROs)...
Eli Lilly wins approval of anti-obesity pill orforglipron
Wednesday, April 1, 2026 – Thursday, April 2 - Now Eli Lilly has an obesity pill, too.
On Wednesday, the FDA approved orforglipron, the agency announced. It will be sold as Foundayo, and Lilly has previously said it plans to ...
Should you microdose Ozempic? Experts are split on risks vs benefits
Wednesday, April 1, 2026 – Thursday, April 2 - Microdosing GLP-1 drugs is trending on social media and supported by some doctors, but experts warn the practice lacks a standard protocol and may undermine weight-loss results.
Lilly wins approval of anti-obesity pill orforglipron, setting up new battle with Novo
Wednesday, April 1, 2026 – Thursday, April 2 - Now Eli Lilly has an obesity pill, too.
On Wednesday, the FDA approved orforglipron, the agency announced. It will be sold as Foundayo, and Lilly said it plans to sell a ...
Ambrosia Eyes Next-Generation Small Molecule GLP-1s With $100M Series B
Wednesday, April 1, 2026 – Thursday, April 2 - While peptides are currently the dominant approach to GLP-1 agonism, Ambrosia Biosciences is pursuing a small-molecule approach.
Phase 3b Data Presented at AAD Annual Meeting Show Lilly’s Taltz (ixekizumab) plus Zepbound (tirzepatide) Delivered Superior Efficacy for Adults with Psoriatic Arthritis and Obesity
Tuesday, March 31, 2026 – Wednesday, April 1 - INDIANAPOLIS, March 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from the TOGETHER-PsA open-label Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide)...
Novo Nordisk Launches First and Only Multi-Month Subscription Program for FDA-Approved Wegovy, Offering Savings of up to $1,200/year
Tuesday, March 31, 2026 – Wednesday, April 1 - PLAINSBORO, N.J., March 31, 2026 /PRNewswire/ -- Novo Nordisk today announced a new multi-month subscription program for Wegovy® (semaglutide) that provides eligible self-pay patients who enroll in the program through select telehealth providers...